tirzepatide trials A 72-week trial compared the two leading GLP-1 medications in adults with obesity (no diabetes). The results: ✓ Tirzepatide: 20.2% weight loss ✓ Semaglutide: 13.7% weight loss But weight loss isn't the Tirzepatide: First Approval | Drugs

Accessed May 1, 2026

Pak Raffaello M

Quick Answer: Splitting Wegovy doses is not recommended as the pre-filled pens are single-use devices that cannot be safely or accurately divided, and dose-splitting is not supported by clinical evidence

Regular follow-ups to monitor your progress, assess any side effects, and review your weight loss goals are essential for determining the best course of action

For example, if cravings start creeping back after being under control, it might mean your current dose isnt as effective anymore

* Based on a 2023 survey by Cerner Enviza of 500 doctors who recommend weight loss programs to patients.